DeltaMetrics' professional team offers
extensive project management experience and in-depth knowledge of the
behavioral healthcare field.
Durell, M.D., President and CEO
Dr. Durell’s professional experiences bring together primary
scientific research, the day-to-day management and oversight of
inpatient psychiatric units and detoxification centers, assessment and
evaluation of substance abuse treatment outcomes, and organizational
development and management. As
Associate Director of Science at the National Institute on Drug Abuse,
Dr. Durell was in the forefront of research on substance abuse.
He has organized and conducted primary research into the
biological aspects of affective illness and psychoses, overseen the
medical and financial management of frontline drug treatment centers,
and guided the growth of DeltaMetrics in its development of products
and services to improve behavioral health care treatment.
Cacciola, Ph.D., Senior Vice President & Scientific Director
Dr. Cacciola is a nationally recognized expert on issues related to
diagnostic and psychosocial assessment and the evaluation of treatment
effectiveness for substance abusing and general psychiatric patients.
He has co-authored more than 50 articles in scientific journals
and was an advisor to the DSM-IV Substance Use Disorders Workgroup.
In addition to serving as the Scientific Director at
DeltaMetrics, Dr. Cacciola is also the principal investigator on
He has led the development of DeltaMetrics’ Assessment and
Treatment Outcomes Management System (ATOMS), a multidimensional
instrument battery that measures change and service provision in the
general psychiatric and substance abuse treatment populations as well
as the development of a self-administered version of the Addiction
Dr. Cacciola also directs the production of training materials
and competency measures for the assessment instruments that
DeltaMetrics uses in its survey projects.
Weiss, Ph.D., Director of Research and Evaluation
Dr. Weiss has significant experience in designing feasibility, pilot
and evaluation studies in the behavioral health care field, including
evaluations of mental health treatment services for children,
adolescents and adults. At
DeltaMetrics, he designs research, methodological, and analytic
strategies for treatment outcome data.
Dr. Weiss is part of a team exploring the long-term impact of
treatment for substance abuse disorders, is Principal Investigator on
DeltaMetrics’ TOPPS II project for the State of New York and is the
Associate Project Director for the TOPPS II Technical Assistance
Center. He is a principal
architect in the
DeltaMetrics effort to apply Continuous Quality Improvement (CQI)
principles in State substance abuse treatment systems,
using empirical data to inform treatment improvement
interventions and to monitor treatment improvement progress.
Marlowe, J.D., Ph.D. is a Senior Scientist at DeltaMetrics and Director
of Criminal Justice Research at the Treatment Research Institute.
He is also an Adjunct Associate Professor of Psychiatry at the
University of Pennsylvania School of Medicine and the MCP/Hahnemann
University School of Medicine, and a Lecturer in Law at the Villanova
University School of Law. A
lawyer and clinical psychologist, Dr. Marlowe’s research focuses on
diversion programs and coercive interventions for substance abusing
offenders. He is
currently the Principal Investigator on two grants jointly funded by
NIDA and CSAT that are investigating the specific effects of judicial
status hearings on drug court outcomes.
Dr. Marlowe has also received continued funding from NIDA to
develop a procedure for characterizing and measuring both coercive and
non-coercive pressures in drug abuse treatment.
He has served as Co-Principal Investigator and Project Director
on an ONDCP-funded evaluation of a diversion program for drug-involved
juvenile offenders, as well as on all three evaluations of the adult
Breaking The Cycle Initiatives funded by NIJ.
For DeltaMetrics, Dr. Marlowe has begun developing criminal
justice research and evaluation initiatives that may eventually
include data collection and case management systems for use by drug
McKay, Ph.D., Senior Scientist
Dr. James McKay is a Senior Scientist at DeltaMetrics and an Associate
Professor of Psychology at
the University of Pennsylvania. He
is also he Scientific Director of the Penn-VA Center for Studies of
Addiction. Dr. McKay is
the author or coauthor of over 95 journal articles and book chapters,
and the recipient of a number of grants from National Institute on
Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism.
He has also served as Principal
Investigator on DeltaMetrics projectsfunded by the Center for
Substance Abuse Treatment, including two projects for the states of
Illinois and Washington. Dr. McKay’s work has focused on the evaluation of primary
and continuing care treatments for alcohol and cocaine use disorders,
comparisons of outcomes following inpatient and outpatient
rehabilitation treatments, and evaluations of patient placement
Geary, Director of Operations
Ms. Geary is a seasoned administrator who oversees
the logistical operation of all projects conducted by
DeltaMetrics. Ms. Geary
and her staff provide start-up and logistical project support, manage
telecommunications and oversee data management. Ms. Geary also works
closely with other organization executives to create strategies that
best address the needs of its public and private sector clients.
Catone, Director of Government Relations
Ms. Catone is DeltaMetrics’ chief liaison with its State and federal
She came to DeltaMetrics with extensive public sector
experience, having served for six years as Legislative Director for a
Member of Congress and six years in State government.
Catone works with professional staff to help anticipate
regulatory trends and address public sector interests as DeltaMetrics
products and services are developed. Because demonstrations of
treatment improvement and accountability are a priority for government
clients, Catone has been actively involved in shaping DeltaMetrics’
CQI initiative and has helped guide its expansion into automation and
State systems building.
Ms. Catone is also active on the operational side of the
organization, helping to uphold DeltaMetrics reputation for
responsiveness to the day-to-day concerns of its public sector
Keller, Vice President of Business Development
Mr. Keller has an extensive background in sales, marketing and
business development, having held senior leadership positions with
various healthcare service companies including hospital information
systems and healthcare television syndication, medical judgment
services, employee assistance programs (EAPs) and managed behavioral
healthcare organizations (MBHOs). Mr. Keller’s experience in the
behavioral health care industry includes
marketing and sales of an outpatient psychotherapy assessment
and treatment outcomes tracking instrument that was developed to
enhance the clinical supervision and case management process for EAPs,
managed care organizations and several Fortune 500 employers.
At DeltaMetrics, Mr. Keller is integrally involved in
development of automated instruments and systems to measure and
improve treatment effectiveness in public and private sector treatment
Foltz, Ph.D., Senior Scientist
As a Research Psychologist at DeltaMetrics, Dr. Foltz is primarily
responsible for analysis of treatment outcome data and contributes to
other methodological and evaluation activities. She conducts analyses
that apply advanced statistical procedures and case mix adjustment
strategies to data collected over multiple assessment points; and she
develops and employs strategies to test and maintain the quality of
short-and long-term outcome data. As a contributor to the development
and evaluation of assessment instruments, she reviews instrument
integrity and performs psychometric analyses of measurement data. Dr.
Foltz also consults with staff and other psychologists on statistical
issues and applications.